lunava
medis pharma pty ltd - leflunomide -
repso
teva b.v. - leflunomide - arthritis, rheumatoid; arthritis, psoriatic - immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a ‘disease-modifying antirheumatic drug’ (dmard);active psoriatic arthritis.recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.
apo-leflunomide tablet
apotex inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents
pms-leflunomide tablet
pharmascience inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents
phl-leflunomide tablet
pharmel inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents
dom-leflunomide tablet
dominion pharmacal - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents
mylan-leflunomide tablet
mylan pharmaceuticals ulc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents
ntp-leflunomide tablet
teva canada limited - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents
leflunomide tablet
sanis health inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents
odan-leflunomide tablet
odan laboratories ltd - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents